SEO-ABM

Analytical module

Stage II


Analytical stage – chromatographic studies

At this stage of the project, an interdisciplinary team of researchers, PhD students and students is developing and validating analytical methods for determining vancomycin and cefuroxime in SEO and biological material.

The work includes developing and validating a high-performance liquid chromatography (HPLC) method compliant with the monographs of the European Pharmacopoeia. The method will enable determination of both antibiotics, their potential degradation products and impurities in the active pharmaceutical ingredients (APIs) and finished products. Stability studies are also being conducted to assess the stability of the active substances in suspensions following homogenisation and during storage under different conditions and in different types of packaging.

In addition, an advanced liquid chromatography–tandem mass spectrometry (LC-MS/MS) method is being developed, using mass spectrometric detection to provide high analytical sensitivity and selectivity. This method will enable detection of even trace amounts of antibiotics in biological material (tear fluid and ocular tissues) following in vivo studies. It will also allow identification of impurities migrating from packaging materials, which is essential for assessing compatibility between the formulation and its container.

The analytical stage also includes developing methods for extracting vancomycin and cefuroxime from biological material to ensure effective sample preparation, as well as a microbiological method for determining vancomycin concentrations in the API and SEO formulations. The latter will complement the instrumental analytical methods and enable assessment of the biological activity of this active substance.

The ultimate outcome of this project stage will be a comprehensive set of analytical methods meeting the requirements of both preclinical studies and subsequent routine quality control of the medicinal product. These methods will enable a full assessment of the stability profile, quality and safety of the antibiotics under investigation in the new ophthalmic formulation.